Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Dr Kumar's take on the Stony Brook p53 article in Nature... "I need to get our paper out. This paper is excellent support of our work."

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
http://www.sciencedaily.com/releases/2015/05/150525115933.htm
http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14430.html

i fwd'd the article to the company and got back Dr. Kumar's comments this morning. (also was given "okay" to post here).... obviously exciting to see one of the main researchers excited to read an outside study confirming Kevetrin's MOA.

DR KUMAR'S RESPONSE

This Nature paper is very interesting and proves previous assumption that mutation in p53 gives rise to oncogenic gain of functions that promotes malignant progression, metastasis and chemo-resistance. Stabilization of mutant p53 is controlled by HSP90/HDAC6 axis. First time, in this paper it has been shown that in animals, depletion of mutant p53 leads to improvement in survival of the mice.

This paper confirms our results with Kevetrin. We have also observed that Kevetrin decreases the HDAC6 (ASCO poster 2013) . HSP90 and its positive regulator HDAC6 are major determinants of mutant p53 stabilization. Decrease in HDAC6 by Kevetrin correlates with induction of mutant p53 degradation and tumor apoptosis and ultimately improvement in survival, as shown in recent nature paper.

I need to get our paper out. This paper is excellent support of our work.

///

btw, can't say enough about KMBJN's knowledge and willingness to share--insights helping us learn up on current p53 research, even if a lot of it goes over heads, well, at least mine.